Analysts Issue Forecasts for Personalis FY2029 Earnings

Personalis, Inc. (NASDAQ:PSNL - Free Report) - Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Personalis in a report issued on Monday, January 27th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of $0.35 for the year. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Personalis' current full-year earnings is ($1.40) per share.

Other equities analysts have also recently issued research reports about the company. Lake Street Capital lifted their price target on Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and set a $7.25 price target on shares of Personalis in a report on Wednesday, January 8th.

Personalis Trading Down 2.6 %

Shares of NASDAQ PSNL traded down $0.14 during mid-day trading on Tuesday, reaching $5.22. The company had a trading volume of 586,728 shares, compared to its average volume of 1,179,835. Personalis has a 1-year low of $1.12 and a 1-year high of $7.20. The stock has a market cap of $368.79 million, a PE ratio of -3.11 and a beta of 1.75. The company has a 50-day moving average price of $4.97 and a two-hundred day moving average price of $4.75.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. During the same quarter in the previous year, the business posted ($0.51) earnings per share.

Hedge Funds Weigh In On Personalis

Institutional investors and hedge funds have recently modified their holdings of the stock. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock worth $81,000 after acquiring an additional 4,504 shares in the last quarter. nVerses Capital LLC acquired a new position in Personalis in the 3rd quarter worth about $40,000. SG Americas Securities LLC purchased a new stake in shares of Personalis during the 4th quarter worth about $63,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Personalis during the 4th quarter worth about $87,000. Finally, International Assets Investment Management LLC lifted its holdings in shares of Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after buying an additional 17,082 shares during the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.